Omniscience Pharmaceuticals Inc.
A carefully integrated array of genomics, bioinformatics, and advanced cloning methods to identify and control metabolic pathways of microorganisms is the driver behind Omniscience Pharmaceuticals Inc.'s strategy for disovering new antibiotics.
You may also be interested in...
The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
A former employee of Biogen is officially charged in China for allegedly jeopardizing public health, Wuhan tests 10 million residents, India approves remdesivir.